October 15, 2019
Ancestry, a consumer genomic testing company focused on family history, is now turning to the health space with its launch of AncestryHealth. The new product is aimed at giving customers insights into the health risks associated with their genes and family history.
As part of the new services customers can get tests that are ordered by doctors. The service will also provide education resources...
June 13, 2019
Genome Medical — a company that offers patient-facing virtual visits and provider-facing consultations with genetic experts — has raised $23 million in Series B funding. The round brings Genome Medical to $46 million in total funding.
The round was led by Echo Health Ventures, with participation from LRVHealth, Casdin Capital, Perceptive Advisors, Manatt Venture Fund and Dreamers Fund, as well as...
May 20, 2019
MyHeritage, an Israeli company that has been doing ancestry-related genetic testing since 2016, has announced a new product that brings the company into the health-focused consumer DNA testing space alongside the likes of 23andMe.
MyHeritage DNA Health+Ancestry is a single test that includes a wide-range of genetic aptitudes for possible health conditions: specifically, the company will offer 11...
March 27, 2019
Direct-to-consumer gene tests like Ancestry.com and 23andMe are increasingly informing consumers about gene alterations that could signal health risks. But those tests look at only a few positions on particular genes, as opposed to medical sequencing that is much more thorough. And, according to a 2018 study by Ambry Genetics in Genetics in Medicine, these results can be wrong — the study showed...
March 11, 2019
At SXSW in Austin this weekend, consumer genomics company 23andMe unveiled its latest test, a predisposition report on Type 2 diabetes.
The test, which has not undergone FDA clearance and does not purport to diagnose a condition, is designed to help people understand when they’re at a higher-than-normal risk for Type 2 diabetes so they can alter their lifestyle. To assist with the latter piece,...
November 15, 2018
Tattoo circuits. Researchers from Carnegie Mellon University and the University of Coimbra have unveiled a method of printing thin circuits that could better enable wearable computation. The low-cost alloy is attached to a stretchable tattoo paper that adheres to the skin when wet, similarly to the decorative tattoos worn by children.
"This is a breakthrough in the printed electronics area,"...
October 19, 2018
Yesterday morning Helix, an early player in the consumer genomics field, announced the launch of its DNA Product Studio. The tool aims to boost the development of new genomics apps and tests for Helix’s partners.
Helix’s model uses third party partners that are experts in a specific arena to develop products. Meanwhile Helix provides sample collection, DNA sequencing, and secures data that the...
September 10, 2018
From ancestry to wine pallet preferences, consumer genomics have fueled both popular curiosity and public discourse. Now MyVytalics, a relative newcomer in the space that focuses on healthy aging, is teaming up with major player in the consumer genomics space Helix to release a new personal genomics app that will look at how genes play in to sleep patterns and nutrition. In the future, the two...
August 24, 2018
23andMe has emailed developers a warning that an API permitting use of anonymized customer datasets for third-party app development will be shut down in approximately two weeks, CNBC reports.
While the raw data will remain available to clinical research partners such as GlaxoSmithKline, which invested $300 million this year to gain access to the genetic testing startup’s DNA database for drug...
23andMe kits at a Beverly Hills event in 2017. Credit: Matt Winkelmeyer, Getty Images
July 25, 2018
23andMe on Wednesday announced that GlaxoSmithKline has invested $300 million to gain exclusive access to the genetic testing startup’s DNA database.
The deal comes as GlaxoSmithKline amid reports that GSK is weighing the possibility of a company breakup and investors contending that synergies between consumer markets and big pharma are inherently limited and that GSK’s pharmaceuticals business...